ORGO vs. NLTX, MREO, PEPG, CRBP, ADCT, ANRO, ATAI, ANL, TERN, and FBLG
Should you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Neoleukin Therapeutics (NLTX), Mereo BioPharma Group (MREO), PepGen (PEPG), Corbus Pharmaceuticals (CRBP), ADC Therapeutics (ADCT), Alto Neuroscience (ANRO), Atai Life Sciences (ATAI), Adlai Nortye (ANL), Terns Pharmaceuticals (TERN), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical preparations" industry.
Organogenesis (NASDAQ:ORGO) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment.
Organogenesis received 46 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 66.21% of users gave Organogenesis an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
Organogenesis has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.
In the previous week, Organogenesis had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for Organogenesis and 0 mentions for Neoleukin Therapeutics. Organogenesis' average media sentiment score of 0.00 equaled Neoleukin Therapeutics'average media sentiment score.
Organogenesis presently has a consensus price target of $4.83, indicating a potential upside of 73.24%. Neoleukin Therapeutics has a consensus price target of $30.00, indicating a potential downside of 14.77%. Given Organogenesis' higher probable upside, equities research analysts plainly believe Organogenesis is more favorable than Neoleukin Therapeutics.
Organogenesis has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
49.6% of Organogenesis shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 34.0% of Organogenesis shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Organogenesis has a net margin of 1.14% compared to Neoleukin Therapeutics' net margin of 0.00%. Organogenesis' return on equity of 1.81% beat Neoleukin Therapeutics' return on equity.
Summary
Organogenesis beats Neoleukin Therapeutics on 14 of the 15 factors compared between the two stocks.
Get Organogenesis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organogenesis Competitors List
Related Companies and Tools
